Skip to main content
Erschienen in: Odontology 2/2022

17.10.2021 | Original Article

Synergistic effect of thymoquinone and nystatin in the treatment of oral candidiasis; an in vitro study

verfasst von: Özge Özdal Zincir, Umut Özdal, Özge Ünlü, Mehmet Demirci, Ahmet Bülent Katiboğlu, Edibe Egil, Gülay Altan Şallı

Erschienen in: Odontology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

The effectiveness of antifungal agents may be insufficient against resistant strains in some cases of oral candidiasis. The aim of this study was to evaluate the antifungal effect of thymoquinone against Candida albicans, Candida tropicalis, Candida glabrata and Candida krusei strains and the synergistic antifungal activity of these strains in combination with nystatin. To evaluate in vitro antifungal activity and interactions between thymoquinone and nystatin, substances were tested against Candida albicans ATCC 10,231, C. tropicalis ATCC 750, C.krusei ATCC 6258 and C. glabrata ATCC 2001 standard strains both individually and combinationally via microdilution method. MIC and ΣFIC index value were analysed. The Kruskal Wallis test and Bonferroni test were used for statistical evaluations. Statistical significance was set at p < 0.05. A statistically significant difference was observed between the mean ranks of all Candida species and doses of thymoquinone, nystatin, and the combination thymoquinone-nystatin (p < 0.05). MIC values for thymoquinone were determined as 15 μg/mL for C. albicans, C. tropicalis and C. krusei while it was 30 μg/mL for C. glabrata. Moreover, MIC for nystatin was found as 1.875 μg/mL for C. albicans, C. tropicalis and C. krusei, whereas it was 7.5 μg/mL in C. glabrata. Interaction assays and ΣFIC index value revealed that, TQ and nystatin have a synergistic effect against to all strains. Thymoquinone was found to have antifungal activity on Candida species and synergistic effect when combined with nystatin.
Literatur
1.
Zurück zum Zitat Coutinho HDM. Factors influencing the virulence of Candida Spp. W Indian Med J. 2009;58(2):160–3.PubMed Coutinho HDM. Factors influencing the virulence of Candida Spp. W Indian Med J. 2009;58(2):160–3.PubMed
2.
Zurück zum Zitat de Castro RD, de Souza TM, Bezerra LM, Ferreira GL, Costa EM, Cavalcanti AL. Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro study. BMC Complement Altern Med. 2015;15:417.CrossRef de Castro RD, de Souza TM, Bezerra LM, Ferreira GL, Costa EM, Cavalcanti AL. Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro study. BMC Complement Altern Med. 2015;15:417.CrossRef
3.
Zurück zum Zitat Mangueira DFB, Mangueira LFB, Diniz MFFM. Candidose oral. R bras ci Saúde. 2010;14(2):69–72.CrossRef Mangueira DFB, Mangueira LFB, Diniz MFFM. Candidose oral. R bras ci Saúde. 2010;14(2):69–72.CrossRef
4.
Zurück zum Zitat Capistrano HM, Assis EM, Leal RM, Alvarez-Leite ME, Brener S, Bastos EM. Brazilian Green própolis compared to miconazole gel in the treatment of Candida-associated denture stomatitis. Evid Based Complement Alternat Med. 2013;2013:947980.CrossRef Capistrano HM, Assis EM, Leal RM, Alvarez-Leite ME, Brener S, Bastos EM. Brazilian Green própolis compared to miconazole gel in the treatment of Candida-associated denture stomatitis. Evid Based Complement Alternat Med. 2013;2013:947980.CrossRef
5.
Zurück zum Zitat Bondaryk M, Kurzatkowski W, Staniszewska M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postępy Dermatol Alergol. 2013;30(5):293–301.CrossRef Bondaryk M, Kurzatkowski W, Staniszewska M. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postępy Dermatol Alergol. 2013;30(5):293–301.CrossRef
6.
Zurück zum Zitat Kamikawa Y, Mori Y, Nagayama T, Fujisaki J, Hirabayashi D, Sakamoto R, et al. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013. BMC Oral Health. 2014;14:14.CrossRef Kamikawa Y, Mori Y, Nagayama T, Fujisaki J, Hirabayashi D, Sakamoto R, et al. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013. BMC Oral Health. 2014;14:14.CrossRef
7.
Zurück zum Zitat Freires IA, Furletti VF, Sartoratto A, Alencar SM, Figueira GM, Murata RM, et al. Coriandrum sativum L. (coriander) essential oil: antifungal activity and mode of action on Candida spp., and molecular targets affected in human whole-genome expression. PLoS ONE. 2014;9(6):e99086.CrossRef Freires IA, Furletti VF, Sartoratto A, Alencar SM, Figueira GM, Murata RM, et al. Coriandrum sativum L. (coriander) essential oil: antifungal activity and mode of action on Candida spp., and molecular targets affected in human whole-genome expression. PLoS ONE. 2014;9(6):e99086.CrossRef
8.
Zurück zum Zitat Wong SSW, Samaranayake LP, Seneviratne CJ. In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. Drug Discov Today. 2014;19(11):1721–30.CrossRef Wong SSW, Samaranayake LP, Seneviratne CJ. In pursuit of the ideal antifungal agent for Candida infections: high-throughput screening of small molecules. Drug Discov Today. 2014;19(11):1721–30.CrossRef
9.
Zurück zum Zitat Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections. Periodontol. 2000;2009(49):39–59. Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections. Periodontol. 2000;2009(49):39–59.
10.
Zurück zum Zitat Sklenar Z, Scigel V, Horackova K, Slanar O. Compounded preparations with nystatin for oral and oromucosal administration. Acta Pol Pharm. 2013;70(4):759–62.PubMed Sklenar Z, Scigel V, Horackova K, Slanar O. Compounded preparations with nystatin for oral and oromucosal administration. Acta Pol Pharm. 2013;70(4):759–62.PubMed
11.
Zurück zum Zitat Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev. 2002;4:CD002033. Gotzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev. 2002;4:CD002033.
12.
Zurück zum Zitat Jabalameli Z, Sabzghabaee A, Mohaghegh M, Maherolnaghsh M, Safavizadeh H, Dehghan P. Antifungal susceptibility of candida species ısolated from cancer patients with oral lesions undergoing chemotherapy. Int J Infect. 2017;4:e14178.CrossRef Jabalameli Z, Sabzghabaee A, Mohaghegh M, Maherolnaghsh M, Safavizadeh H, Dehghan P. Antifungal susceptibility of candida species ısolated from cancer patients with oral lesions undergoing chemotherapy. Int J Infect. 2017;4:e14178.CrossRef
13.
Zurück zum Zitat Forouzanfar F, Bazzaz BS, Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci. 2014;17(12):929–38.PubMedPubMedCentral Forouzanfar F, Bazzaz BS, Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran J Basic Med Sci. 2014;17(12):929–38.PubMedPubMedCentral
14.
Zurück zum Zitat Shafiq H, Ahmad A, Masud T, Kalem M. Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci. 2014;17(12):967–79.PubMedPubMedCentral Shafiq H, Ahmad A, Masud T, Kalem M. Cardio-protective and anti-cancer therapeutic potential of Nigella sativa. Iran J Basic Med Sci. 2014;17(12):967–79.PubMedPubMedCentral
15.
Zurück zum Zitat Darakhshan S, Bidmeshki Pour A, Hosseinzadeh Colagar A, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95–96:138–58.CrossRef Darakhshan S, Bidmeshki Pour A, Hosseinzadeh Colagar A, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res. 2015;95–96:138–58.CrossRef
16.
Zurück zum Zitat Kara MI, Erciyas K, Altan AB, Ozkut M, Ay S, Inan S. Thymoquinone accelerates new bone formation in the rapid maxillary expansion procedure. Arch Oral Biol. 2012;57(4):357–63.CrossRef Kara MI, Erciyas K, Altan AB, Ozkut M, Ay S, Inan S. Thymoquinone accelerates new bone formation in the rapid maxillary expansion procedure. Arch Oral Biol. 2012;57(4):357–63.CrossRef
17.
Zurück zum Zitat Mahmoudvand H, Sepahvand A, Jahanbakhsh S, Ezatpour B, Ayatollahi Mousavi SA. Evaluation of antifungal activities of the essential oil and various extracts of Nigella sativa and its main component, thymoquinone against pathogenic dermatophyte strains. J Mycol Med. 2014;24(4):e155–61.CrossRef Mahmoudvand H, Sepahvand A, Jahanbakhsh S, Ezatpour B, Ayatollahi Mousavi SA. Evaluation of antifungal activities of the essential oil and various extracts of Nigella sativa and its main component, thymoquinone against pathogenic dermatophyte strains. J Mycol Med. 2014;24(4):e155–61.CrossRef
18.
Zurück zum Zitat Botelho MG. Fractional inhibitory concentration index of combinations of antibacterial agents against cariogenic organisms. J Dent. 2000;28(8):565–70.CrossRef Botelho MG. Fractional inhibitory concentration index of combinations of antibacterial agents against cariogenic organisms. J Dent. 2000;28(8):565–70.CrossRef
19.
Zurück zum Zitat Jenkinson HF, Lamont RJ. Oral microbial communities in sickness and in health. Trends Microbiol. 2005;13(12):589–95.CrossRef Jenkinson HF, Lamont RJ. Oral microbial communities in sickness and in health. Trends Microbiol. 2005;13(12):589–95.CrossRef
20.
Zurück zum Zitat Avila M, Ojcius DM, Yilmaz O. The oral microbiota: living with a permanent guest. DNA Cell Biol. 2009;28(8):405–11.CrossRef Avila M, Ojcius DM, Yilmaz O. The oral microbiota: living with a permanent guest. DNA Cell Biol. 2009;28(8):405–11.CrossRef
21.
Zurück zum Zitat Aas JA, Barbuto SM, Alpagot T, Olsen I, Dewhirst FE, Paster BJ. Subgingival plaque microbiota in HIV positive patients. J Clin Periodontol. 2007;34(3):189–95.CrossRef Aas JA, Barbuto SM, Alpagot T, Olsen I, Dewhirst FE, Paster BJ. Subgingival plaque microbiota in HIV positive patients. J Clin Periodontol. 2007;34(3):189–95.CrossRef
22.
Zurück zum Zitat Millsop JW, Fazel N. Oral candidiasis. Clin Dermatol. 2016;34(4):487–94.CrossRef Millsop JW, Fazel N. Oral candidiasis. Clin Dermatol. 2016;34(4):487–94.CrossRef
23.
Zurück zum Zitat Dangi YS, Soni ML, Namdeo KP. Oral candidiasis: a review. Int J Pharm Pharm Sci. 2010;2(4):36–41. Dangi YS, Soni ML, Namdeo KP. Oral candidiasis: a review. Int J Pharm Pharm Sci. 2010;2(4):36–41.
24.
Zurück zum Zitat Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74(4):323–31.CrossRef Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74(4):323–31.CrossRef
25.
Zurück zum Zitat Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther. 1998;20(1):40–57.CrossRef Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther. 1998;20(1):40–57.CrossRef
26.
Zurück zum Zitat Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78(922):455–9.CrossRef Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78(922):455–9.CrossRef
27.
Zurück zum Zitat Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.CrossRef Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.CrossRef
28.
Zurück zum Zitat WHO Guidelines Approved by the Guidelines Review Committee. Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults. Geneva: World Health Organization. Copyright (c) World Health Organization 2014; 2014. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults. Geneva: World Health Organization. Copyright (c) World Health Organization 2014; 2014.
29.
Zurück zum Zitat Kundu J, Kim DH, Kundu JK, Chun KS. Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKalpha as upstream targets. Food Chem Toxicol. 2014;65:18–26.CrossRef Kundu J, Kim DH, Kundu JK, Chun KS. Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKalpha as upstream targets. Food Chem Toxicol. 2014;65:18–26.CrossRef
30.
Zurück zum Zitat Alhebshi AH, Gotoh M, Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid beta-induced neurotoxicity. Biochem Biophys Res Commun. 2013;433(4):362–7.CrossRef Alhebshi AH, Gotoh M, Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid beta-induced neurotoxicity. Biochem Biophys Res Commun. 2013;433(4):362–7.CrossRef
31.
Zurück zum Zitat Al-Bayaty F, Kamaruddin A, Ismail M, Abdulla M. Formulation and evaluation of a new biodegradable periodontal chip containing thymoquinone in a chitosan base for the management of chronic periodontitis. J Nanomater. 2013;3:397308. Al-Bayaty F, Kamaruddin A, Ismail M, Abdulla M. Formulation and evaluation of a new biodegradable periodontal chip containing thymoquinone in a chitosan base for the management of chronic periodontitis. J Nanomater. 2013;3:397308.
32.
Zurück zum Zitat Gholamnezhad Z, Havakhah S, Boskabady MH. Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol. 2016;190:372–86.CrossRef Gholamnezhad Z, Havakhah S, Boskabady MH. Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol. 2016;190:372–86.CrossRef
34.
Zurück zum Zitat Omar OM, Khattab NM, Khater DS. Nigella sativa oil as a pulp medicament for pulpotomized teeth: a histopathological evaluation. J Clin Pediatr Dent. 2012;36(4):335–42.CrossRef Omar OM, Khattab NM, Khater DS. Nigella sativa oil as a pulp medicament for pulpotomized teeth: a histopathological evaluation. J Clin Pediatr Dent. 2012;36(4):335–42.CrossRef
35.
Zurück zum Zitat Piras A, Rosa A, Marongiu B, Porcedda S, Falconieri D, Dessì MA, et al. Chemical composition and in vitro bioactivity of the volatile and fixed oils of Nigella sativa L. extracted by supercritical carbon dioxide. Ind Crops Prod. 2013;46:317–23.CrossRef Piras A, Rosa A, Marongiu B, Porcedda S, Falconieri D, Dessì MA, et al. Chemical composition and in vitro bioactivity of the volatile and fixed oils of Nigella sativa L. extracted by supercritical carbon dioxide. Ind Crops Prod. 2013;46:317–23.CrossRef
36.
Zurück zum Zitat Khan MA, Aljarbou AN, Khan A, Younus H. Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model. Int J Biol Macromol. 2015;76:203–8.CrossRef Khan MA, Aljarbou AN, Khan A, Younus H. Liposomal thymoquinone effectively combats fluconazole-resistant Candida albicans in a murine model. Int J Biol Macromol. 2015;76:203–8.CrossRef
37.
Zurück zum Zitat Johnson MD, Macdougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. J Antimicrob Chemother. 2004;48(3):693–715.CrossRef Johnson MD, Macdougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. J Antimicrob Chemother. 2004;48(3):693–715.CrossRef
38.
Zurück zum Zitat Ning Y, Ling J, Wu CD. Synergistic effects of tea catechin epigallocatechin gallate and antimycotics against oral Candida species. Arch Oral Biol. 2015;60(10):1565–70.CrossRef Ning Y, Ling J, Wu CD. Synergistic effects of tea catechin epigallocatechin gallate and antimycotics against oral Candida species. Arch Oral Biol. 2015;60(10):1565–70.CrossRef
39.
Zurück zum Zitat Lu M, Li T, Wan J, Li X, Yuan L, Sun S. Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. Int J Antimicrob Agents. 2017;49(2):125–36.CrossRef Lu M, Li T, Wan J, Li X, Yuan L, Sun S. Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. Int J Antimicrob Agents. 2017;49(2):125–36.CrossRef
Metadaten
Titel
Synergistic effect of thymoquinone and nystatin in the treatment of oral candidiasis; an in vitro study
verfasst von
Özge Özdal Zincir
Umut Özdal
Özge Ünlü
Mehmet Demirci
Ahmet Bülent Katiboğlu
Edibe Egil
Gülay Altan Şallı
Publikationsdatum
17.10.2021
Verlag
Springer Singapore
Erschienen in
Odontology / Ausgabe 2/2022
Print ISSN: 1618-1247
Elektronische ISSN: 1618-1255
DOI
https://doi.org/10.1007/s10266-021-00667-4

Weitere Artikel der Ausgabe 2/2022

Odontology 2/2022 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.